Incidence of Bacterial Diseases has Augmented the Launch of Generic Version of Ertapenem Leading to the Ertapenem Market Growth

Published: May 2022

The global ertapenem market is anticipated to grow at a considerable CAGR during the forecast period (2022-2028). Ertapenem is also prescribed for patients undergoing certain types of surgery that poses a risk of infection. Incidence of various bacterial diseases is increasing rapidly that is accelerating the demand for ertapenem drug. Pneumonia acquired in hospital settings due to longer patient stays, is often difficult to treat and exists as the comorbidity to various chronic diseases such as cancer, organ transplant. etc. It also interferes with the disease treatment and may be fatal if not treated with broad-spectrum antibiotics such as carbapenem-based antibiotics. 

Browse the full report description of “Global Ertapenem Market Size, Share & Trends Analysis Report by Type (Purity: Above 98% and Purity: Above 99%), and by Application (Injection and Tablet) Forecast 2022-2028” at https://www.omrglobal.com/industry-reports/ertapenem-market

Various regional as well as global pharmaceutical companies are assessing feasibility for possible re- launch of generic version of ertapenem in various regions. For instance, in 2021 Dr. Reddy's Laboratories Ltd. is committed to delivering low-cost, innovative medicines to help people live healthier lives. Dr. Reddy offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, and differentiated formulations through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics, and Proprietary Products. The gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology are major therapeutic areas of focus. Dr. Reddy is present in markets all over the world. 

Market Coverage

The market number available for – 2022-2028

Base year- 2022

Forecast period- 2022-2028

Segment Covered- 

o By Type

o By Application

Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

Competitive Landscape- Kopran Ltd., Canagen Pharma Inc., Conder Co., Taiwan Savior Lifetec Corp., Xiamen Amoipharm Chem. Co. Ltd., Fuan Pharmaceutical (Grp.) Co. Ltd., Pfizer Inc., Merck Co. & Inc., Sumitomo Dainippon Pharma Co., Ltd., and others.

Key questions addressed by the report

What is the market growth rate?

Which segment and region dominate the market in the base year?

Which segment and region will project the fastest growth in the market?

How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

Who is the leader in the market?

How are players addressing challenges to sustain growth?

Where is the investment opportunity?

Global Ertapenem market Market Report Segment

By Type

Purity: Above 98%

Purity: Above 99%

By Application

Injection

Tablet

Global Ertapenem market Market Report Segment by Region

North America

United States

Canada

Europe

UK

Germany

Italy

Spain

France

Rest of Europe 

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific 

Rest of the World

Latin America 

Middle East & Africa


To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/ertapenem-market